Sorin Group S.p.A. Announces CE Mark Approval And First Implant Of MEMO 3D ReChord
A mitral valve annuloplasty ring with innovative chordal guiding system standardizes artificial chord replacement
MILAN--(BUSINESS WIRE)--Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today CE mark certification for its new MEMO 3D ReChord mitral valve annuloplasty ring that is now commercially available in Europe. The first implant was presented at the 28th Annual Meeting of the European Association for Cardiothoracic Surgery (EACTS) by Mattia Glauber, M.D.
Mitral valve repair represents the gold standard technique for patients presenting with mitral valve regurgitation. It enables preservation of the native valve and allows patients to resume a normal lifestyle after surgery.
MEMO 3D ReChord is the latest innovation from Sorin Group that offers a portfolio of solutions for all types of mitral valve disease. It is the ultimate repair device designed to deliver better patient outcomes while facilitating the surgical procedure. MEMO 3D ReChord features an innovative chordal guiding system, making artificial chordae tendineae replacement a routine and standardized procedure.
Unique design elements include a Carbofilm coating and laser cut Ni-Ti technology for truly physiologic performance.
Dr. Glauber, who presented the first implantation of the ring at the EACTS techno-college session, commented on the technology’s ease of use: “The MEMO 3D ReChord is very easy to place, and the chordal system is indeed very useful, especially in minimally invasive surgery. I have tried it in both anterior and posterior prolapse cases, and it worked nicely in both situations without the need for further adjustments. Of course, we need to gain more experience to be able to guide surgeons to the correct indication, but this first experience was extremely positive,” said Dr. Glauber.
“In my opinion, this device has the potential to change the approach to mitral valve repair. We are facing a situation where we are resecting less and less while using more artificial chords; therefore, a system that helps to standardize artificial chord replacement is very timely,” continued Dr. Glauber.
“MEMO 3D ReChord is the latest result of our continuous effort to bring innovation to cardiac surgery teams. It represents a great opportunity to advance our presence in the mitral valve repair market,” said Michel Darnaud, President Cardiac Surgery Business Unit, Sorin Group. “It has been engineered to fulfill the growing demand for faster and more reproducible artificial chord replacement. We are committed to setting high standards in design and performance to support patients and cardiac surgeons in the management of mitral valve disease.”
About Sorin Group
Sorin Group (www.sorin.com) is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With over 3, 500 employees worldwide,Sorin Group focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement prostheses) and Cardiac Rhythm Management (pacemakers, defibrillators and non invasive monitoring to diagnose arrhythmias and deliver anti-arrhythmia therapies as well as cardiac resynchronization devices for heart failure treatment) Every year, over one million patients are treated with Sorin Group devices in more than 100 countries.
For more information, please visit www.sorin.com.
Contacts
Gabriele Mazzoletti
Director, Corporate Communications
Sorin Group
Tel: +39 02 69969785
Mobile: +39 348 9792201
e-mail: corporate.communications@sorin.com
or
Francesca Rambaudi
Director, Investor Relations
Sorin Group
Tel: +39 02 69969716
e-mail: investor.relations@sorin.com
Help employers find you! Check out all the jobs and post your resume.
MILAN--(BUSINESS WIRE)--Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today CE mark certification for its new MEMO 3D ReChord mitral valve annuloplasty ring that is now commercially available in Europe. The first implant was presented at the 28th Annual Meeting of the European Association for Cardiothoracic Surgery (EACTS) by Mattia Glauber, M.D.
Mitral valve repair represents the gold standard technique for patients presenting with mitral valve regurgitation. It enables preservation of the native valve and allows patients to resume a normal lifestyle after surgery.
MEMO 3D ReChord is the latest innovation from Sorin Group that offers a portfolio of solutions for all types of mitral valve disease. It is the ultimate repair device designed to deliver better patient outcomes while facilitating the surgical procedure. MEMO 3D ReChord features an innovative chordal guiding system, making artificial chordae tendineae replacement a routine and standardized procedure.
Unique design elements include a Carbofilm coating and laser cut Ni-Ti technology for truly physiologic performance.
Dr. Glauber, who presented the first implantation of the ring at the EACTS techno-college session, commented on the technology’s ease of use: “The MEMO 3D ReChord is very easy to place, and the chordal system is indeed very useful, especially in minimally invasive surgery. I have tried it in both anterior and posterior prolapse cases, and it worked nicely in both situations without the need for further adjustments. Of course, we need to gain more experience to be able to guide surgeons to the correct indication, but this first experience was extremely positive,” said Dr. Glauber.
“In my opinion, this device has the potential to change the approach to mitral valve repair. We are facing a situation where we are resecting less and less while using more artificial chords; therefore, a system that helps to standardize artificial chord replacement is very timely,” continued Dr. Glauber.
“MEMO 3D ReChord is the latest result of our continuous effort to bring innovation to cardiac surgery teams. It represents a great opportunity to advance our presence in the mitral valve repair market,” said Michel Darnaud, President Cardiac Surgery Business Unit, Sorin Group. “It has been engineered to fulfill the growing demand for faster and more reproducible artificial chord replacement. We are committed to setting high standards in design and performance to support patients and cardiac surgeons in the management of mitral valve disease.”
About Sorin Group
Sorin Group (www.sorin.com) is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With over 3, 500 employees worldwide,Sorin Group focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement prostheses) and Cardiac Rhythm Management (pacemakers, defibrillators and non invasive monitoring to diagnose arrhythmias and deliver anti-arrhythmia therapies as well as cardiac resynchronization devices for heart failure treatment) Every year, over one million patients are treated with Sorin Group devices in more than 100 countries.
For more information, please visit www.sorin.com.
Contacts
Gabriele Mazzoletti
Director, Corporate Communications
Sorin Group
Tel: +39 02 69969785
Mobile: +39 348 9792201
e-mail: corporate.communications@sorin.com
or
Francesca Rambaudi
Director, Investor Relations
Sorin Group
Tel: +39 02 69969716
e-mail: investor.relations@sorin.com
Help employers find you! Check out all the jobs and post your resume.